ArticleBMC infectious diseases2025
Epidemiological characteristics and spatiotemporal distribution of hepatitis C in southeast coastal areas of China from 2015 to 2022.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- National trends in acute viral hepatitis in China from 1990-2023: An analysis of the Global Burden of Disease 2023 update.Chinese medical journal · 2026Article
- Trends and forecasting of reported hepatitis B and hepatitis C incidence in Hainan Province, China, 2005-2020.Frontiers in epidemiology · 2026Article
- Analysis of genetic evolution and molecular transmission of hepatitis C virus in key areas of the southeast coast of China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe purpose of this study was to analyze the epidemiological characteristics and spatial-temporal distribution characteristics of hepatitis C in Fujian Province, China, from 2015 to 2022, and to provide reference for the risk identification, early warning and prevention and control measures of hepatitis C in Fujian Province.
methodsThe incidence data of hepatitis C in Fujian Province from 2015 to 2022 were collected from the China Information System for Disease Control and Prevention. Descriptive epidemiology method and JRP 4.9.1.0 software were used to analyze the epidemiological characteristics of hepatitis C in Fujian Province from 2015 to 2022. ArcGIS 10.8 software was used for spatial autocorrelation analysis of the reported incidence of hepatitis C, and SaTScan 10.1.3 software was used for spatio-temporal scanning analysis.
resultsA total of 18,712 cases of hepatitis C were reported in Fujian Province from 2015 to 2022, and the annual reported incidence showed a decreasing trend (AAPC =-10.4, P < 0.001). Males were more affected, accounting for 55.7% (n = 10,429) of all reported hepatitis C cases compared to 44.3% (n = 8,283) for females. Among all age groups, the number of cases in people aged 40-60 was the largest, accounting for 43.2%. Autocorrelation analysis showed that the reported cases of hepatitis C from 2015 to 2022 were clustered, and the global Moran´s I values were all greater than 0 (P < 0.001). Local autocorrelation analysis showed that the high-high concentration area of hepatitis C incidence was relatively fixed and concentrated in the Putian city. The spatial and temporal scanning analysis detected one largest possible agglomeration area, Xiuyu District of Putian city, and two type II agglomeration areas were mainly distributed in economically developed cities along the coastal line.
conclusionThe reported incidence of hepatitis C in Fujian province showed a downward trend from 2015 to 2022, and there were obvious epidemic characteristics and spatial-temporal clustering of hepatitis C. Attention should be paid not only to the key population of 40-60 years old males in rural areas and the key gathering areas in Putian City, but also to the incidence of hepatitis C in southeast coastal areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.